唑来膦酸治疗骨转移患者的颌骨坏死累积发生率:SWOG S0702研究
多中心前瞻性观察队列SWOG S0702纳入3491例接受唑来膦酸治疗骨转移的癌症患者,随访3年确认的颌骨坏死(ONJ)累积发生率为2.8%(95%CI 2.3%-3.5%),多发性骨髓瘤患者最高(4.3%)。计划给药间隔小于5周、戴义齿和当前吸烟与ONJ风险升高相关,而牙齿总数较多与风险降低相关。
要点
- 唑来膦酸治疗骨转移患者3年ONJ累积发生率为2.8%。
- 多发性骨髓瘤患者3年ONJ累积发生率最高,为4.3%。
- 计划给药间隔<5周者ONJ风险显著升高(HR 4.65)。
核心结论
- 接受唑来膦酸治疗骨转移的癌症患者3年ONJ累积发生率为2.8%。
- 癌症类型、口腔健康状况和给药频率与ONJ风险相关。
研究设计与样本
- 多中心前瞻性观察队列研究(SWOG Cancer Research Network S0702)。
- 纳入3491例可评估的骨转移患者,随访3年,基线及每6个月收集医疗、牙科和患者报告表。
- ONJ定义为颌面部暴露骨区域持续超过8周且无同期颅面部放疗。
主要发现
- 1年、2年、3年ONJ累积发生率分别为0.8%(95%CI 0.5%-1.1%)、2.0%(95%CI 1.5%-2.5%)、2.8%(95%CI 2.3%-3.5%)。
- 3年累积发生率在多发性骨髓瘤患者中最高,为4.3%(95%CI 2.8%-6.4%)。
临床怎么用
- 对接受唑来膦酸治疗的骨转移患者,应评估癌症类型、口腔健康和吸烟状态以分层ONJ风险。
- 计划给药间隔小于5周可能增加ONJ风险,需关注给药频率。
- 建议在治疗前进行牙科检查并维护口腔健康。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. OBJECTIVE: To define the cumulative incidence of ONJ at 3 years in patients receiving zoledronic acid for MBD from any malignant neoplasm. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective observational cohort study (SWOG Cancer Research Network S0702) included patients with MBD with either limited or no prior exposure to BMAs and a clinical care plan that included use of zoledronic acid within 30 days of registration. Medical, dental, and patient-reported outcome forms were submitted at baseline and every 6 months. Follow-up was 3 years. Osteonecrosis of the jaw was defined using established criteria. Data were collected from January 30, 2009, to December 13, 2013, and analyzed from August 24, 2018, to August 6, 2020. INTERVENTIONS/EXPOSURES: Cancer treatments, BMAs, and dental care were administered as clinically indicated. MAIN OUTCOMES AND MEASURES: Cumulative incidence of confirmed ONJ, defined as an area of exposed bone in the maxillofacial region present for more than 8 weeks with no concurrent radiotherapy to the craniofacial region. Risk factors for ONJ were also examined. RESULTS: The SWOG S0702 trial enrolled 3491 evaluable patients (1806 women [51.7%]; median age, 63.1 [range, 2.24-93.9] years), of whom 1120 had breast cancer; 580, myeloma; 702, prostate cancer; 666, lung cancer; and 423, other neoplasm. A baseline dental examination was performed in 2263 patients (64.8%). Overall, 90 patients developed confirmed ONJ, with cumulative incidence of 0.8% (95% CI, 0.5%-1.1%) at year 1, 2.0% (95% CI, 1.5%-2.5%) at year 2, and 2.8% (95% CI, 2.3%-3.5%) at year 3; 3-year cumulative incidence was highest in patients with myeloma (4.3%; 95% CI, 2.8%-6.4%). Patients with planned zoledronic acid dosing intervals of less than 5 weeks were more likely to experience ONJ than patients with planned dosing intervals of 5 weeks or more (hazard ratio [HR], 4.65; 95% CI, 1.46-14.81; P = .009). A higher rate of ONJ was associated with fewer total number of teeth (HR, 0.51; 95% CI, 0.31-0.83; P = .006), the presence of dentures (HR, 1.83; 95% CI, 1.10-3.03; P = .02), and current smoking (HR, 2.12; 95% CI, 1.12-4.02; P = .02). CONCLUSIONS AND RELEVANCE: As the findings show, the cumulative incidence of ONJ after 3 years was 2.8% in patients receiving zoledronic acid for MBD. Cancer type, oral health, and frequency of dosing were associated with the risk of ONJ. These data provide information to guide stratification of risk for developing ONJ in patients with MBD receiving zoledronic acid.
引用
- Van Poznak CH, Unger JM, Darke AK, et al. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. JAMA Oncol. 2021. PMID: 33331905. doi:10.1001/jamaoncol.2020.6353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。